Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Public ClinicalTrials.gov record NCT06956235. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Study identification
- NCT ID
- NCT06956235
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2025
- Primary completion
- Apr 1, 2026
- Completion
- Jun 5, 2028
- Last update posted
- Sep 14, 2026
2025 – 2028
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cahaba Dermatology & Skin Health Center ( Site 0012) | Birmingham | Alabama | 35244 | — |
| Medical Dermatology Specialists ( Site 0027) | Phoenix | Arizona | 85006 | — |
| Northwest Arkansas Clinical Trials Center, PLLC ( Site 0049) | Rogers | Arkansas | 72758 | — |
| Northridge Clinical Trials ( Site 0004) | Northridge | California | 91325 | — |
| Integrative Skin Science and Research ( Site 0015) | Sacramento | California | 95815 | — |
| Olympian Clinical Research ( Site 0010) | Tampa | Florida | 33615 | — |
| Skin Care Physicians of Georgia ( Site 0033) | Macon | Georgia | 31217 | — |
| Dawes Fretzin Clinical Research Group, LLC ( Site 0025) | Indianapolis | Indiana | 46250 | — |
| Beth Israel Deaconess Medical Center ( Site 0044) | Boston | Massachusetts | 02215 | — |
| Revival Research Institute, LLC ( Site 0005) | Troy | Michigan | 48084 | — |
| Mount Sinai Doctors - East 85th Street ( Site 0050) | New York | New York | 10028 | — |
| DJL Clinical Research, PLLC ( Site 0021) | Charlotte | North Carolina | 28211 | — |
| University Hospitals Cleveland Medical Center ( Site 0046) | Cleveland | Ohio | 44106 | — |
| Wright State Physicians Health Center ( Site 0041) | Fairborn | Ohio | 45324 | — |
| Palmetto Clinical Trial Services, LLC ( Site 0023) | Anderson | South Carolina | 29621 | — |
| Arlington Center for Dermatology ( Site 0045) | Arlington | Texas | 76011 | — |
| Texas Dermatology Research Center ( Site 0019) | Dallas | Texas | 75246 | — |
| Reveal Research Institute ( Site 0018) | Frisco | Texas | 75033 | — |
| Progressive Clinical Research ( Site 0020) | San Antonio | Texas | 78213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06956235, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2026 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06956235 live on ClinicalTrials.gov.